drugset
drugset / Trial / NCT03816631

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

NCT03816631 ↗

Phase 1 Completed 42 enrolled Janssen-Cilag International NV
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function.

Timeline

Start
2019-05-28
Primary completion
2020-04-27
Completion
2020-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimodivir Small molecule 600 mg Oral

Indications

No indication recorded.